Stock listing

Munich:RB0 Regenxbio Inc. Aktie

German listing (Munich) of Regenxbio Inc. · home listing NASDAQ:RGNX

Follow Regenxbio Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RGNX

$7.15 USD +0.23 (+3.2%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RGNX

Since Jul 6, 2026 -51.8% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$6.95 – $7.27 USDOct 19, 2026
Volume
1.30M sharesOct 19, 2026
Market value
$472.0M USDAt the close on Oct 19, 2026 · price × 66.01M shares outstanding
Regenxbio Inc. logo
Ticker
Munich:RB0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • REGENXBIO (NASDAQ:RGNX) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:00 AM ET

    Watch Transcript

  • REGENXBIO (NASDAQ:RGNX) Q1 2026 Earnings Call

    Thu, May 14, 2026 · 8:00 AM ET

    Watch Transcript

  • REGENXBIO (NASDAQ:RGNX) Q4 2025 Earnings Call

    Thu, Mar 05, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

Oct 12, 2026

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Sep 24, 2026

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Aug 25, 2026

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Aug 24, 2026

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 6, 2026

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

Aug 3, 2026

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Jul 18, 2026

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Jul 17, 2026

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Jun 29, 2026

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

Jun 24, 2026

All Regenxbio Inc. news

Financings

  • Public offering of common stock and pre-funded warrants

    Aug 6, 2026

    Closed: US$108M raised · US$9 a share · Morgan Stanley +3

    Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Leerink Partners (co-lead), Mizuho (co-lead)

    Use of proceeds: Extend cash runway into Q4 2027 and support the planned AFFINITY RISE ex-U.S. randomized-controlled trial of RGX-202 in 1H 2027

    Announced Jul 17, 2026 · Closed Aug 6, 2026

Read by 6ix AI from the company's releases

Decks

Regenxbio Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 220 in all · newest Oct 12, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Aug 6, 2026
Decks
14 decks · latest September 2026

Where Regenxbio Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RGNX · Home listingNASDAQUnited StatesUSD
gettex:RB0gettexGermanyEUR
LS Exchange:A140E0LS ExchangeGermanyEUR
Tradegate:RB0TradegateGermanyEUR
Lang & Schwarz:A140E0Lang & SchwarzGermanyEUR
Frankfurt:RB0FrankfurtGermanyEUR
BOATS:RGNXBOATSUnited StatesUSD
Munich:RB0 · This pageMunichGermanyEUR
Dusseldorf:RB0DusseldorfGermanyEUR
Stuttgart:RB0StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Regenxbio Inc.